Pharmacological properties of the naturally occurring Phe-124-Cys variant of the human 5-HT1B receptor: changes in ligand binding, G-protein coupling and second messenger formation.

The aim of this study was to analyse whether substitution of phenylalanine in position 124 of the human (h) 5-HT1B receptor by cysteine, a naturally occurring variant of this receptor, modifies not only ligand binding, but also G-protein coupling and second messenger formation. Stably transfected rat C6 glioma cells, which express either the h5-HT1B variant receptor (VR) or the wild-type receptor (WTR) were used. In saturation experiments with [3H]5-carboxamidotryptamine ([3H]5-CT), the maximum binding (Bmax) of the VR amounted to only 60% of that to WTR. In competition experiments with 1 nM [3H]5-CT, the following 5-HT receptor ligands exhibited a higher affinity for the mutant receptor than for the WTR: L-694,247, 5-CT, 5-HT, sumatriptan (agonists listed at decreasing order of potency) and SB-224289 (a selective h5-HT1B receptor inverse agonist with competitive antagonistic properties). In contrast, the mixed 5-HT1B/1D receptor antagonist GR-127935 exhibited equal affinity for both isoforms. The efficacy of L-694,247, 5-CT, 5-HT and sumatriptan in stimulating [35S]GTPgammaS binding (a measure of G protein coupling) to membranes of cells expressing the VR was approximately 50-65% lower compared to membranes of cells expressing the WTR, but their potency was 2.8-3.6-fold higher. SB-224289, which decreased [35S]GTPgammaS binding when given alone, but not GR-127935, was more potent in antagonizing the stimulatory effect of 5-CT on [35S]GTPgammaS binding to membranes expressing the VR compared to membranes expressing the WTR. In whole cells expressing the VR, 5-CT and sumatriptan inhibited the forskolin-stimulated cAMP accumulation 3.2-fold more potently than in cells expressing the WTR. In conclusion, our data suggest that the Phe-124-Cys mutation modifies the pharmacological properties of the h5-HT1B receptor and may account for pharmacogenetic differences in the action of h5-HT1B receptor ligands. Thus, the sumatriptan-induced vasospasm which occurs at low incidence as a side-effect in migraine therapy may be related to the expression of the (124-Cys)h5-HT1B receptor in patients with additional pathogenetic factors such as coronary heart disease.

[1]  H. Bönisch,et al.  Modified ligand binding to the naturally occurring Cys-124 variant of the human serotonin 5-HT1B receptor. , 1999, Pharmacogenetics.

[2]  B. Fredholm,et al.  Signaling via A2A adenosine receptor in four PC12 cell clones , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[3]  M. Göthert,et al.  Genetic Variation in Human 5‐HT Receptors: Potential Pathogenetic and Pharmacological Role a , 1998, Annals of the New York Academy of Sciences.

[4]  D. Middlemiss,et al.  SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity , 1998, British journal of pharmacology.

[5]  A. Brown,et al.  5‐HT1B receptor‐mediated contractions in human temporal artery: evidence from selective antagonists and 5‐HT receptor mRNA expression , 1998, British journal of pharmacology.

[6]  M. Ferrari,et al.  Coronary side-effect potential of current and prospective antimigraine drugs. , 1998, Circulation.

[7]  P. Pauwels,et al.  Pharmacological analysis of G‐protein activation mediated by guinea‐pig recombinant 5‐HT1B receptors in C6‐glial cells: similarities with the human 5‐HT1B receptor , 1998, British journal of pharmacology.

[8]  D. Middlemiss,et al.  Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  M. J. Burton,et al.  SB-216641 and BRL-15572 – compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  P. Pauwels,et al.  How Efficacious are 5-HT1B/D Receptor Ligands: an Answer from GTPγS Binding Studies with Stably Transfected C6-glial Cell Lines , 1997, Neuropharmacology.

[11]  P. Pauwels,et al.  Selective antagonism of human 5-HT1D and 5-HT1B receptor-mediated responses in stably transfected C6-glial cells by ketanserin and GR 127,935. , 1996, European journal of pharmacology.

[12]  P. Pauwels,et al.  Functional effects of the 5-HT1D receptor antagonist GR 127,935 at human 5-HT1Dα, 5-HT1Dβ, 5-HT1A and opposum 5-HT1B receptors , 1995 .

[13]  M. Nöthen,et al.  Identification of Genetic Variation in the Human Serotonin 1Dβ Receptor Gene , 1994 .

[14]  H. Posival,et al.  Variable Participation of 5‐HT1‐Like Receptors and 5‐HT2 Receptors in Serotonin‐Induced Contraction of Human Isolated Coronary Arteries: 5‐HT1‐Like Receptors Resemble Cloned 5‐HT1Dβ Receptors , 1994, Circulation.

[15]  C. Montigny,et al.  Current advances and trends in the treatment of depression. , 1994, Trends in pharmacological sciences.

[16]  P P Humphrey,et al.  International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). , 1994, Pharmacological reviews.

[17]  M Briley,et al.  Neurobiological mechanisms involved in antidepressant therapies. , 1993, Clinical neuropharmacology.

[18]  R. Lefkowitz,et al.  Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. , 1993, Trends in pharmacological sciences.

[19]  J. Ottervanger,et al.  Transmural myocardial infarction with sumatriptan , 1993, The Lancet.

[20]  E. Parker,et al.  A Single Amino Acid Difference Accounts for the Pharmacological Distinctions Between the Rat and Human 5‐Hydroxytryptamine1B Receptors , 1993, Journal of neurochemistry.

[21]  R. McGuffin,et al.  Conversion of the human 5-HT1D beta serotonin receptor to the rat 5-HT1B ligand-binding phenotype by Thr355Asn site directed mutagenesis. , 1992, Biochemical pharmacology.

[22]  B. O'dowd,et al.  A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.

[23]  A. Brooks,et al.  Cardiorespiratory distress after sumatriptan given by injection. , 1992, BMJ.

[24]  E. Zifa,et al.  5-Hydroxytryptamine receptors. , 1992, Pharmacological reviews.

[25]  V. Williamson,et al.  Thrombosis and pulmonary embolism. , 1992, BMJ.

[26]  M. Göthert.  Presynaptic Serotonin Receptors in the Central Nervous System , 1990, Annals of the New York Academy of Sciences.

[27]  M. Caron,et al.  Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. , 1988, Science.

[28]  H. Okayama,et al.  High-efficiency transformation of mammalian cells by plasmid DNA. , 1987, Molecular and cellular biology.

[29]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[30]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[31]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.